4　その他
⑴　契約手続において使用する言語及び通貨
日本語及び日本国通貨。
⑵　入札保証金及び契約保証金　免除。
⑶　入札者に要求される事項　この一般競争に参加を希望する者は、封印した入札書に本公告に示した物品を納入できることを証明する書類を添付して入札書の受領期限までに提出しなければならない。入札者は、開札日の前日までの間において、学長から当該書類に関し説明を求められた場合は、それに応じなければならない。
⑷　入札の無効　本公告に示した競争参加資格のない者の提出した入札書、入札者に求められる義務を履行しなかった者の提出した入札書、その他入札説明書による。
⑸　契約書作成の要否　要。
⑹　落札者の決定方法　本公告に示した物品を納入できると学長が判断した入札者であって、国立大学法人新潟大学契約事務取扱規程第11条の規定に基づいて作成された予定価格の制限の範囲内で最低価格をもって有効な入札を行った入札者を落札者とする。ただし、落札者となるべき者の入札価格によっては、その者により当該契約の内容に適合した履行がなされないおそれがあると認められるときは、予定価格の制限の範囲内の価格をもって入札した次順位者を落札者とする。
⑺　手続における交渉の有無　無。
⑻　その他　詳細は、入札説明書による。なお、入札説明書等で当該調達に関する環境上の条件を定めた調達であると示されている場合は、十分理解した上で応札すること。

5　Summary
⑴　Official in charge of disbursement of the procuring entity : Tatsuo Ushiki, President, National University Corporation Niigata University
⑵　Classification of the products to be procured : 4
⑶　Nature and quantity of the products to be purchased :
A　Patisiran Sodium (8.8mg 4.4mL／vial) 30vials
B　Pembrolizumab (Genetical Recombination) (100mg 4mL／vial) 1,300vials
C　Sugammadex Sodium (200mg 10mL 10-vials／case) 300cases
D　Gilteritinib Fumarate (40mg 42-tablets／case) 30cases
E　Blinatumomab (Genetical Recombination) (35μg／vial (with infusion stabilization liquid)) 300vials
F　Olaparib (150mg 56tablets／case) 300-cases
G　Durvalumab (Genetical Recombination) (120mg 2.4mL／vial) 300vials
H　Durvalumab (Genetical Recombination) (500mg 10mL／vial) 200vials
I　Palivizumab (Genetical Recombination) (100mg 1mL／vial) 400vials
J　Benralizumab (Genetical Recombination) (30mg 1mL／syringe) 90syringes
K　Risankizumab (Genetical Recombination) (75mg 0.83mL／syringe) 100syringes
L　Asfotase alfa (Genetical Recombination) (40mg 1mL／vial) 60vials
M　Asfotase alfa (Genetical Recombination) (80mg 0.8mL／vial) 300vials
N　Eculizumab (Genetical Recombination) (300mg 30mL／vial) 100vials
O　Ravulizumab (Genetical Recombination) (300mg 30mL／vial) 200vials
P　Adalimumab (Genetical Recombination) (40mg 0.4mL／syringe) 500syringes
Q　Bictegravir sodium Emtricitabine Tenofovir alafenamide fumarate (30-tablets／vial)　400vials
R　Mepolizumab (Genetical Recombination) (100mg 1mL／kit) 300kits
S　Eftrenonacog Alfa (Genetical Recombination) (3,000IU ／ vial (with solution)) 50vials
T　Nusinersen Sodium (12mg 5mL／vial) 9vials
U　Methotrexate (1,000mg 40mL ／ vial) 700vials
V　Dasatinib Hydrate (50mg 30tablets／case) 90cases
W　Lenalidomide Hydrate (5mg 40-capsules／case) 100cases
X　Abatacept (Genetical Recombination) (250mg／vial) 500vials
Y　Ipilimumab (Genetical Recombination) (50mg 10mL／vial) 100vials
Z　Cetuximab (Genetical Recombination) (100mg 20mL／vial) 2,200vials
AA　Pegfilgrastim (Genetical Recombination) (3.6mg 0.36mL／syringe) 600-syringes
AB　Romiplostim (Genetical Recombination) (250μg／vial) 300vials
AC　Aflibercept (Genetical Recombination) (2mg 0.05mL／syringe) 500syringes
AD　Tirabrutinib Hydrochloride (80mg 28tablets／case) 200cases
AE　Nivolumab (Genetical Recombination) (240mg 24mL／vial) 900vials
AF　Paclitaxel (100mg／vial) 700vials
AG　Palonosetron hydrochloride (0.75mg 50m l5bags／case) 600cases
AH　Denosumab (Genetical Recombination) (120mg 1.7mL／vial) 900vials
AI　Tocilizumab (Genetical Recombination) (80mg 4mL／vial) 1,500vials
AJ　Tocilizumab (Genetical Recombination) (200mg 10mL／vial) 1,400vials
AK　Tocilizumab (Genetical Recombination) (162mg 0.9mL／kit) 1,700kits
AL　Bevacizumab (Genetical Recombination) (100mg 4mL／vial) 2,200vials
AM　Bevacizumab (Genetical Recombination) (400mg 16mL／vial) 1,800vials
AN　Satralizumab (Genetical Recombination) (120mg 1mL ／ syringe) 50syringes
AO　Atezolizumab (Genetical Recombination) (1,200mg 20mL／vial) 200vials
AP　Pertuzumab (Genetical Recombination) (420mg 14mL／vial) 400vials
AQ　Emicizumab (Genetical Recombination) (150mg 1mL／vial) 20vials
AR　Rituximab (Genetical Recombination) (500mg 50mL／vial) 200vials
AS　Lanreotide Acetate (120mg／syringe) 80syringes
AT　Ustekinumab (Genetical Recombination) (45mg 0.5mL ／ syringe) 300-syringes
AU　Golimumab (Genetical Recombination) (50mg 0.5mL／kit) 300kits
AV　Infliximab (Genetical Recombination) (100mg／vial) 3,200vials
AW　Ramucirumab (Genetical Recombination) (100mg 10mL／vial) 300vials
AX　Ramucirumab (Genetical Recombination) (500mg 10mL／vial) 90vials
AY　Polyethylene glycol treated human normal immunoglobulin (10g 100mL／vial) 600vials
AZ　Cabozantinib Malate (20mg 30-tablets／case) 100cases
BA　Brentuximab Vedotin (Genetical Recombination) (50mg／vial) 80vials
BB　Freeze-dried polyethylene glycol treated human normal immunoglobulin (5g／vial (with soluation)) 1,300vials
⑷　Delivery period : From 1 April, 2022 through 31 March, 2023
⑸　Delivery place : Niigata University Medical and Dental Hospital
⑹　Qualifications for participating in the tendering procedures : Suppliers eligible for participating in the proposed tender are those who shall :
A　not come under Article 4 over the past one year and Article 3 of the Regulation concerning the Contract for Niigata University Furthermore, minors, Person under Conservatorship or Person under Assistance that obtained the consent necessary for concluding a contract may be applicable under cases of special reasons within the said clause,
B　have the Grade A or Grade B qualification during fiscal 2021 in the Kanto・Koshinetsu area in sales of product for participating in tenders by Single qualification for every ministry and agency,